End-of-day quote
Shenzhen S.E.
03:30:00 14/05/2024 am IST
|
5-day change
|
1st Jan Change
|
16.98
CNY
|
-0.88%
|
|
-5.09%
|
-21.79%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Capitalization
1 |
3,219
|
2,693
|
3,968
|
3,486
|
3,684
|
Enterprise Value (EV)
1 |
2,618
|
2,067
|
3,126
|
2,739
|
3,226
|
P/E ratio
|
23.4
x
|
23.9
x
|
22.9
x
|
28.6
x
|
29.1
x
|
Yield
|
2.1%
|
3.34%
|
1.21%
|
0.83%
|
1.11%
|
Capitalization / Revenue
|
2.57
x
|
1.93
x
|
3.08
x
|
2.53
x
|
2.35
x
|
EV / Revenue
|
2.09
x
|
1.48
x
|
2.42
x
|
1.98
x
|
2.06
x
|
EV / EBITDA
|
15.9
x
|
11.8
x
|
15.4
x
|
13.9
x
|
16.6
x
|
EV / FCF
|
44.8
x
|
46.3
x
|
72.5
x
|
106
x
|
61.7
x
|
FCF Yield
|
2.23%
|
2.16%
|
1.38%
|
0.95%
|
1.62%
|
Price to Book
|
3.5
x
|
2.79
x
|
3.01
x
|
2.55
x
|
2.45
x
|
Nbr of stocks (in thousands)
|
1,89,225
|
1,89,225
|
2,01,728
|
2,01,728
|
1,97,397
|
Reference price
2 |
17.01
|
14.23
|
19.67
|
17.28
|
18.66
|
Announcement Date
|
29/03/19
|
02/04/20
|
16/04/21
|
15/04/22
|
31/03/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
1 |
873.2
|
1,255
|
1,396
|
1,290
|
1,380
|
1,568
|
EBITDA
1 |
160.3
|
164.8
|
175.6
|
202.9
|
197.2
|
193.9
|
EBIT
1 |
127.1
|
126.2
|
138.1
|
162
|
151
|
133
|
Operating Margin
|
14.56%
|
10.06%
|
9.89%
|
12.56%
|
10.94%
|
8.48%
|
Earnings before Tax (EBT)
1 |
123.5
|
137.3
|
153.7
|
210.7
|
172.6
|
146.9
|
Net income
1 |
87.4
|
108.7
|
112.3
|
163.7
|
119.8
|
127.3
|
Net margin
|
10.01%
|
8.66%
|
8.04%
|
12.69%
|
8.68%
|
8.12%
|
EPS
2 |
0.6136
|
0.7277
|
0.5945
|
0.8609
|
0.6040
|
0.6414
|
Free Cash Flow
1 |
118
|
58.39
|
44.65
|
43.11
|
25.92
|
52.3
|
FCF margin
|
13.51%
|
4.65%
|
3.2%
|
3.34%
|
1.88%
|
3.33%
|
FCF Conversion (EBITDA)
|
73.57%
|
35.44%
|
25.43%
|
21.25%
|
13.15%
|
26.97%
|
FCF Conversion (Net income)
|
134.98%
|
53.72%
|
39.77%
|
26.33%
|
21.63%
|
41.08%
|
Dividend per Share
|
-
|
0.3567
|
0.4756
|
0.2378
|
0.1427
|
0.2069
|
Announcement Date
|
13/04/18
|
29/03/19
|
02/04/20
|
16/04/21
|
15/04/22
|
31/03/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
57.7
|
602
|
626
|
842
|
747
|
458
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
118
|
58.4
|
44.6
|
43.1
|
25.9
|
52.3
|
ROE (net income / shareholders' equity)
|
29.2%
|
17.8%
|
12.7%
|
15.1%
|
9.91%
|
8.46%
|
ROA (Net income/ Total Assets)
|
9.72%
|
6.64%
|
6.05%
|
6.09%
|
4.69%
|
3.55%
|
Assets
1 |
899.1
|
1,638
|
1,857
|
2,690
|
2,556
|
3,584
|
Book Value Per Share
2 |
2.510
|
4.860
|
5.100
|
6.540
|
6.780
|
7.610
|
Cash Flow per Share
2 |
0.9800
|
3.270
|
2.790
|
4.230
|
3.490
|
3.730
|
Capex
1 |
54.8
|
68.2
|
75.6
|
91
|
87.3
|
68.8
|
Capex / Sales
|
6.27%
|
5.43%
|
5.41%
|
7.05%
|
6.33%
|
4.39%
|
Announcement Date
|
13/04/18
|
29/03/19
|
02/04/20
|
16/04/21
|
15/04/22
|
31/03/23
|
|
1st Jan change
|
Capi.
|
---|
| -21.79% | 468M | | +31.06% | 682B | | +30.35% | 586B | | -3.42% | 364B | | +18.02% | 327B | | +4.27% | 285B | | +15.53% | 240B | | +10.16% | 209B | | -8.14% | 203B | | +8.12% | 165B |
Other Pharmaceuticals
|